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Background: Thrombocytopenia is a common occurrence in cancer patients. Although platelets play an important role in the development of 
acute coronary syndrome, thrombocytopenia does not protect cancer patients from ischemic events. The purpose of this study was to identify 
thrombocytopenia as a predictor of inhospital major adverse cardiovascular events (MACE) in patients treated invasively.
Methods: Between 11/2009 and 8/2011 a total of 380 consecutive cancer patients underwent endovascular procedures. Patients with active 
bleeding, sepsis and acute thrombocytopenia were excluded. Adverse outcomes defined as death, myocardial infarction, stroke and interventional 
complications including bleeding, were evaluated.
Results: Out of the 380 cancer patients treated, 78 (20.5%) had thrombocytopenia (platelets<100K/mm3). Mean platelet count was 49K/ 
mm3 with the lowest being 8K/mm3. Procedures were performed successfully in all patients (100%) utilizing both femoral (60%) and radial (40%) 
access. Out of 78 invasive procedures, 38 (48.7%) were interventional procedures requiring higher ACT and dual antiplatelet therapy. The quartile 
distribution invasive/interventional procedures was: 18/9 with platelet count < 25K/ mm3; 17/10 with platelets 26-50K/mm3; 17/10 with a count 
of 51-75K/mm3 and 26/9 with platelet count 76- 99K/mm3. No significant bleeding complications were identified; one patient had a clinically 
non-significant femoral hematoma. No cardiovascular related deaths occurred.
Conclusions: Chronic thrombocytopenia was not associated with increased major bleeding or major adverse cardiovascular events in a tertiary 
center with expertise in high-risk interventions. Therefore, severe thrombocytopenia should not be the main decision factor for conservative versus 
invasive treatment in cancer patients. An invasive strategy should be also offered to patients with chronic thrombocytopenia.
